27 completed, 2 terminated, 1 recruiting, 1 unknown. 17 Phase 2, 14 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 14, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 14 | Completed 14 |
| Phase 3 | 3 | Terminated 2, Completed 1 |
Follow trebananib: new trials by email Literature Review of trebananib trials Research Report on trebananib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor Pembrolizumab, Trebananib - Advanced Solid Tumor | Phase 1 | Completed | Dana-Farber Cancer Institute | 62 | 2018-05-01 | 2026-07-01 |
| Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma AMG 386, Docetaxel - Urothelial Carcinoma | Phase 2 | Withdrawn | University of Colorado, Denver | 2014-02-01 | 2014-04-29 | |
| Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer AMG 386, AMG 386 Placebo, Pemetrexed - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Amgen | 36 | 2012-08-01 | 2016-06-03 |
| Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate - Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 41 | 2012-08-01 | 2022-06-07 |
| Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Trebananib - Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 16 | 2012-07-01 | 2015-10-19 |
| AMG 386 Drug-Drug Interaction Study With Paclitaxel AMG 386, Paclitaxel - Advanced Solid Tumors | Phase 1 | Completed | Amgen | 35 | 2012-07-01 | 2014-09-23 |
| Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study - Giant Cell Glioblastoma, Glioblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 137 | 2012-06-04 | 2022-07-21 |
| Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus - Adult Solid Neoplasm, Lung Carcinoid Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 21 | 2012-03-01 | 2015-10-06 |
| AMG 386 and Abiraterone for Advanced Prostate Cancer AMG 386, Abiraterone, Prednisone - Prostatic Neoplasms, Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 36 | 2012-02-08 | 2019-03-05 |
| Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Laboratory Biomarker Analysis, Pharmacological Study - Central Nervous System Neoplasm, Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 37 | 2012-02-01 | 2016-10-03 |
| TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer AMG 386, Paclitaxel, AMG 386 Placebo - Fallopian Tube Cancer, Ovarian Cancer | Phase 3 | Terminated | Amgen | 1015 | 2012-01-01 | 2017-02-23 |
| Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia trebananib, cytarabine, laboratory biomarker analysis - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 | Completed | Roswell Park Cancer Institute | 24 | 2011-10-31 | 2022-09-13 |
| A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function AMG 386 + Paclitaxel, AMG 386 - Advanced Solid Tumors, Kidney Disease | Phase 1 | Completed | Amgen | 35 | 2011-09-19 | 2017-11-06 |
| Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Trebananib - Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 35 | 2011-06-06 | 2018-02-23 |
| AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) AMG386 plus PLD, Placebo plus PLD - Fallopian Tube Cancer, Ovarian Cancer | Phase 3 | Terminated | Amgen | 223 | 2011-04-18 | 2017-12-02 |
| Amgen 386 for Recurrent Glioblastoma Amgen 386, Bevacizumab - Glioblastoma Multiforme | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 48 | 2010-12-01 | 2017-07-02 |
| Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer AMG 386, paclitaxel and carboplatin - Carcinoma, Fallopian Tube Cancer | Phase 1 | Completed | Amgen | 27 | 2010-11-01 | 2015-10-14 |
| Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-naïve Metastatic Colorectal Cancer AMG386 and bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Unknown | Austin Health | 40 | 2010-11-01 | 2010-11-30 |
| TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer AMG 386, AMG 386 Placebo, Paclitaxel - Fallopian Tube Cancer, Ovarian Cancer | Phase 3 | Completed | Amgen | 919 | 2010-11-01 | 2016-12-15 |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin - Breast Neoplasms, Breast Cancer | Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 5000 | 2010-03-01 | 2026-05-06 |
Showing 20 of 32. Sign in to see all of them.
Ovarian Neoplasms (7) · Fallopian Tube Neoplasms (6) · Neoplasms (6) · Neoplasm Metastasis (5) · Carcinoma (4) · Breast Neoplasms (3) · Carcinoma, Renal Cell (3) · Colorectal Neoplasms (3) · Brain Neoplasms (2) · Gastrointestinal Neoplasms (2) · Glioblastoma (2) · Hemangiosarcoma (2) · Sarcoma (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1)
Amgen (18) · National Cancer Institute (NCI) (6) · Dana-Farber Cancer Institute (2) · Austin Health (1) · Gynecologic Oncology Group (1) · QuantumLeap Healthcare Collaborative (1) · Roswell Park Cancer Institute (1) · Takeda (1) · University of Colorado, Denver (1)
United States (19) · Belgium (8) · Australia (7) · Canada (7) · Spain (5) · France (4) · Austria (3) · Denmark (3) · Greece (3) · Hong Kong (3) · Italy (3) · Poland (3) · United Kingdom (3) · Germany (2) · Hungary (2)
David Reardon, MD (1) · Eudocia Q Lee (1) · Eunice Wang (1) · Kathleen Moore (1) · Laura Esserman, MD, MBA (1) · Niall Tebbutt (1) · Philippe Bedard (1) · Ravi A Madan, M.D. (1) · Sandra D'Angelo (1) · Sarah Leary (1) · Stephen Hodi, MD (1) · Thomas Flaig, MD (1) · Thomas J Semrad (1)
PMID 37185961, PMID 21796368, PMID 22198468, PMID 22210018, PMID 22623692, PMID 22649152, PMID 22692704, PMID 23124648, PMID 23361051, PMID 25037684, PMID 25747197, PMID 26304872, PMID 27029706, PMID 27406346, PMID 27406347, PMID 28592620, PMID 28851423, PMID 31076365, PMID 32031889, PMID 32053137, PMID 32154928, PMID 32450725, PMID 32701140, PMID 34529000, PMID 34741021, PMID 35623341, PMID 35993306, PMID 36069821, PMID 36456573, PMID 37029329, PMID 37325931, PMID 37407274, PMID 37505107, PMID 38086377, PMID 38180338, PMID 38745646, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39613746, PMID 39625569, PMID 40526879, PMID 40551254, PMID 40639409, PMID 40679371, PMID 40777112, PMID 41879562, PMID 42530945, PMID 42545411, PMID 42619946
U10CA180868 (2), 2009 (1), N01CM00038 (1), P30CA033572 (1), U01CA132123 (1), U10CA021661 (1), U10CA027469 (1), U10CA031946 (1), U10CA180821 (1), UM1CA097452 (1), UM1CA186644 (1)